New hope for inoperable lung cancer patients in trial
NCT ID NCT07082179
Summary
This study is testing whether adding two new immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemotherapy works better for people with stage III non-small cell lung cancer that cannot be removed by surgery. The trial will enroll 33 patients who haven't had previous cancer treatments to see if this combination can shrink tumors and improve outcomes. Researchers will monitor how well patients respond and track side effects throughout treatment and follow-up.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jiangsu Provincial Cancer Hospital
RECRUITINGNanjing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.